Design Therapeutics Inc
designtx.comDesign Therapeutics Inc (NASDAQ: DSGN) is a clinical-stage biopharmaceutical company developing small molecule therapies for serious diseases caused by genetic mutations. The company has generated no product revenue as of the 10-K filed 2026-03-09, financing operations through equity and debt offerings rather than commercial sales. DSGN targets repeat expansion disorders, with disclosed programs addressing Myotonic Dystrophy Type 1 (DM1) and Huntington's Disease (HD). The company operates in a competitive clinical-stage space where numerous programs from other biotechnology and pharmaceutical companies are pursuing DM1 and HD through distinct mechanisms including RNAi, antisense oligonucleotides, antibody-linked conjugates, gene therapy, and peptide-conjugated approaches. Design Therapeutics relies on intellectual property protection, including pending patent applications, as a key asset, though granted patents and their enforceability are not assured.
Products & Services
Clinical-stage small molecule programs targeting repeat expansion disorders, including programs for Myotonic Dystrophy Type 1 and Huntington's Disease. No products have received marketing approval as of the filing date.
Revenue Model
No product revenue as of the 10-K filed 2026-03-09. Operations are funded through public and private equity offerings, debt financings, and potential strategic collaborations or licensing arrangements with third parties.
Customers & Markets
No commercial customers as of the 10-K filed 2026-03-09. Target end markets are patients with genetic repeat expansion disorders, including DM1 and HD.
Geographic Exposure
Based in the United States. References to EU regulatory frameworks including Mutual Recognition Procedure and EU market exclusivity provisions indicate awareness of potential future international markets, but no commercial geographic footprint is disclosed.
Financial Snapshot
Loading...
